3rd Edition Global Longevity Federation

Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease

Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lomecel-B™ for the treatment of mild Alzheimer’s Disease. Lomecel-B™ is a proprietary, scalable, allogeneic, investigational cellular therapy being evaluated across multiple indications, including Alzheimer’s Disease (Phase 2a completed), Aging-related Frailty (Phase 2b completed) and hypoplastic left heart syndrome (HLHS) (Phase 2b ongoing).Readmore

Mayo Clinic scientists define new type of memory loss in older adults

Researchers at Mayo Clinic have established new criteria for a memory-loss syndrome in older adults that specifically impacts the brain's limbic system. It can often be mistaken for Alzheimer's disease. The good news: Limbic-predominant Amnestic Neurodegenerative Syndrome, or LANS, progresses more slowly and has a better prognosis, and is now more clearly defined for doctors working to find answers for memory loss patients.Readmore

VUMC’s Alexander Bick receives a “healthy aging” research award

Vanderbilt’s Alexander Bick, MD, PhD, has received a Hevolution/AFAR New Investigator Award in Aging Biology and Geroscience Research from the American Federation for Aging Research (AFAR) and Hevolution Foundation.Readmore

UNM Center for Memory & Aging Receives $21.7 Million NIH Grant to Fund its Alzheimer’s Disease Research Center

The University of New Mexico’s Center for Memory & Aging has received a five-year $21.7 million program grant from the National Institutes of Health (NIH) to fund its Alzheimer’s Disease Research Center (ADRC).Readmore

UQ research reveals exercise brain boost can last for years

A longitudinal study by University of Queensland researchers has found high-intensity interval exercise improves brain function in older adults for up to 5 years. Readmore

Nutritious diet in midlife linked to healthier aging

Eating a diet rich in fruits, vegetables, whole grains, and unsaturated fats throughout midlife may increase an individual’s odds of aging healthfully, according to a new study by researchers at Harvard T.H. Chan School of Public Health.Readmore

Interleukin Linked to Muscle Loss, Fat Accumulation of Aging

In a new paper appearing in Nature, the team of scientists from Duke-NUS Medical School in Singapore demonstrated in preclinical mouse studies that the protein interleukin-11 (IL11) actively promotes aging, and that giving an anti-IL11 therapy not only counteracts the deleterious effects of aging but also increases lifespan. Readmore

UTSW study identifies RNA molecule that regulates cellular aging

Researchers discover noncoding RNA that plays unexpected role in senescence, which is involved in aging, degenerative diseases, cancer, other conditionsReadmore

Scientists find “master switch” which could hold the key to longer, healthier lives.

Inhibiting IL-11 in mice extends healthy lifespan and reduces hallmarks of diseases associated with ageingReadmore

Eli Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease

The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of AD, with confirmed amyloid pathology.1, 2 Once-monthly Kisunla is the first and only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed, which can result in lower treatment costs and fewer infusions.3-6Readmore

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China China is the Third Country to Launch LEQEMBI Following the United States and Japan

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, announced today that the humanized anti-soluble aggregated amyloid-beta monoclonal antibody “LEQEMBI®” has been launched in China. LEQEMBI received approval in January 2024 as a treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia. China is the third country to launch LEQEMBI following the United States and Japan. Readmore

Damage to synapses caused by Alzheimer’s disease reversed

A novel treatment has been proven to effectively treat cognitive decline in mice with Alzheimer’s disease.Readmore

Cracking the aging code: Insights into lipid changes

Researchers at the RIKEN Center for Integrative Medical Sciences (IMS) have discovered numerous age-related changes in the lipid metabolism of mice, across both organs and sexes. Among these changes was the selective accumulation, throughout the body, of certain lipids produced by gut bacteria as the mice aged. Readmore

Risk factors for faster aging in the brain revealed in new study

Researchers from the Nuffield Department of Clinical Neurosciences at the University of Oxford have used data from UK Biobank participants to reveal that diabetes, traffic-related air pollution and alcohol intake are the most harmful out of 15 modifiable Readmore

Middle-aged brain can predict your future brain health, new review finds

The team led by University College Cork (UCC) researchers reviewed past evidence from human and animal studies to illustrate that during middle age the brain undergoes significant molecular, cellular, and structural changes, and many of these changes haveReadmore

More Schooling is Linked to Slowed Aging and Increased Longevity Two years of education translated to a 2-3 percent slower pace of aging

Participants in the Framingham Heart Study who achieved higher levels of education tended to age more slowly and went on to live longer lives as compared to those who did not achieve upward educational mobility, according to a new study by researchers at Readmore

Researchers Find More Complexity in Aging Brain’s Memory Decline

Researchers from The University of Texas at Dallas Center for Vital Longevity (CVL) have discovered that brain correlates of age-related memory decline are more complicated than previously believed, a finding that could affect efforts to preserve cognitivReadmore

Looking to rewind the aging clock

Harvard researchers create model that better measures biological age, distinguishes between harmful and adaptive changes during life Readmore

Schizophrenia and aging may share a common biological basis Tightly synchronized genetic changes in two types of brain cells may underlie cognitive impairment in both conditions, offering potential therapeutic clues.

Researchers from the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, Harvard Medical School, and McLean Hospital have uncovered a strikingly similar suite of changes in gene activity in brain tissue from people with schiReadmore

Brock-led research uncovers breakthrough in age-related diseases

Newman Sze, Brock University Professor of Health Sciences and Canada Research Chair in Mechanisms of Health and Disease, leads an international team that has uncovered a key link between oxidative stress, aging and chronic diseases, paving the way for posReadmore

TELOMIR PHARMACEUTICALS RELEASES NEW PRE-CLINICAL DATA FOR TELOMIR-1 TO BE PRESENTED AT THE GLOBAL LONGEVITY FEDERATION CONFERENCE IN LAS VEGAS ON MARCH 26TH

Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells Readmore

£3 million UKRI funding to support research into better health, ageing, and wellbeing

The University of Cambridge has received UKRI funding for research on age-related biological changes in model organisms as part of a national collaboration. Readmore

Anti-ageing drug rapamycin improves immune function through endolysosomes, Protection against an increase in pro-inflammatory factors with age

A research group at the Max Planck Institute for Biology of Ageing has discovered in fruit flies that rapamycin activates the so-called endolysosomes, which have a similar function to the stomach in our cells.Readmore

Damage to cell membranes causes cell aging

A new study has found that mechanical damage to the cell membrane may induce cellular senescence in human cells. Readmore

Could a Drug Prevent Hearing Loss from Loud Music and Aging?

Researchers have found a gene that links deafness to cell death in the inner ear in humans – creating new opportunities for averting hearing loss.Readmore

Keys to aging hidden in the leaves

Scientists have known about a particular organelle in plant cells for over a century. However, UC Riverside scientists have only now discovered that organelle’s key role in aging. Readmore

Life span increases in mice when specific brain cells are activated

Brain cells communicate with fat tissue to produce cellular fuel, counteract effects of agingReadmore